H. Lundbeck A/S Navne-Aktier B
- BID
5.66
- ASK
5.695
- 2,455 Units2,444 Units
- 07/23, 18:05:32 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
26.44%
Market Cap
-
P/E Ratio
13.41
Dividend Yield
2.66 %
Earnings per Share
0.43 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 5.66 G | 0 Units |
| PRICE DETERMINATION TIME | 07/23/2026 / 06:04:48 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 5.71 | 5.64 |
| PREV. DAY'S PRICE | 5.7 | (07/22) |
| CHANGE DAY BEFORE | -0.04 | -0.70 % |
| 52 WEEK HIGH / LOW | 6.305 (10/30) | 4.444 (08/04) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.31 | 0.43 | 0.43 | 0.62 | 0.63 |
DIVIDENDS PER SHARE | 0.09 | 0.13 | 0.15 | 0.21 | 0.22 |
DIVIDEND YIELD IN % | 2.14 % | 2.30 % | 2.66 % | - | - |
DIVIDEND GROWTH IN % | 20.26 % | 35.58 % | 21.18 % | - | - |
PRICE - EARNINGS RATIO | 14.19 | 13.03 | 13.41 | 9.22 | 9.01 |
PRICE - BOOK RATIO | 1.47 | 1.64 | 1.72 | - | - |
PRICE - SALES RATIO | 1.63 | 1.86 | 1.76 | - | - |
PRICE - CASH FLOW RATIO | 7.96 | 12.04 | 8.74 | - | - |
Master Data
| WKN | A3DMBV |
| ISIN | DK0061804770 |
| SYMBOL | LDBA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | H. LUNDBECK A/S SER.B DK1 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 3.35 % | 2.52 % | -0.70 % | -3.80 % | 26.44 % | 30.79 % | - | 0.26 % |
| HIGH | 5.74 | 5.92 | 6.12 | 6.18 | 6.31 | 6.57 | - | 6.26 |
| LOW | 5.51 | 5.49 | 5.33 | 4.88 | 4.44 | 3.68 | - | 4.88 |
Dividende
pro Aktie
Company profile
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Operations. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
Structured products for H. Lundbeck A/S Navne-Aktier B
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.